AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Actos shows sustained efficacy over 2-year period.
2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Long-term studies using the oral antidiabetic drug Actos (pioglitazone HCl) alone, and in combination with other oral antidiabetic medications, found that it provided sustained improvements in glycemic control, insulin sensitivity and key lipid parameters over a 104-week period.
The findings were presented at the American Diabetes Association's (ADA) 64th Annual Scientific Sessions.
"Given the clinical challenges of managing diabetes patients over time, and the fact that patients are living longer with diabetes, the data being presented on Actos help physicians better understand the drug's effectiveness over an extended period," said Mehmood Khan, MD, FACE, senior vice president for medical and scientific affairs, Takeda Pharmaceuticals. "Physicians are mindful that sustained improvements in A1C are essential to the long-term health of patients with type 2 diabetes."
These studies, which were all conducted over a 2-year period, compared the effects of Actos either alone or in combination with two other commonly used oral antidiabetic medications: a sulfonylurea (gliclazide) and metformin.
In one study of 1269 patients with type 2 diabetes, four different regimens were evaluated over 2 years of treatment: Actos (15-45 mg/day) or metformin (850-2550 mg/day), added to existing sulfonylurea therapy (gliclazide, 80-320 mg/day); and, using the same dosages, Actos or a sulfonylurea (gliclazide) added to existing metformin therapy.
- Studies show that ACTOS has positive effects on dyslipidemia, insulin...
- Newspaper article from: Biotech Business Week July 5, 2004 700+ words
...Significant beneficial effects of ACTOS were seen on HDL cholesterol...Additionally, the benefits seen with ACTOS were not significantly influenced...body mass index or gender. ACTOS is an oral treatment for type...article was prepared by Biotech Business Week editors from staff and other...
- Combination therapy with Actos improves components of diabetic dyslipidemia.
- Newspaper article from: Biotech Business Week May 31, 2004 700+ words
...treatment, findings showed Actos, at either 30 mg or 45 mg...suggesting that medications like Actos have additional properties...2 diabetes," noted Khan. Actos is known as an insulin sensitizer...article was prepared by Biotech Business Week editors from staff and other...
- Trial assesses Actos in cardiovascular disease progression and type 2 diabetes.
- Newspaper article from: Biotech Business Week July 26, 2004 700+ words
...if the beneficial effects of Actos on cardiovascular risk factors...Previous studies have suggested Actos can provide benefits extending...several large-scale trials, Actos consistently improved components...article was prepared by Biotech Business Week editors from staff and other...
- Drug makers sign deal to develop combined diabetes product from Actos, Fortamet.
- Newspaper article from: Pharma Business Week February 2, 2004 700+ words
...such as this combination of Actos and Fortamet. We are delighted...consequently to the further growth of Actos, which is one of our international...combination of Fortamet with Actos is intended to provide a complementary...article was prepared by Pharma Business Week editors from staff and ...
- 25 Million Actos prescriptions written.
- Newspaper article from: Biotech Business Week September 22, 2003 700+ words
...We're very proud of what Actos has achieved in a short amount of time." Actos was approved in July 1999...patient years. TZDs such as Actos are known as insulin resistance...article was prepared by Biotech Business Week editors from staff and other...
- ACTOS(R) Passes 3.5 Million Prescriptions.
- Press release article from: PR Newswire December 6, 2000 700+ words
...announced that their oral insulin sensitizer, ACTOS(R) (pioglitazone HCl), has passed the 3.5 million-prescription mark. Since ACTOS first became available in the United States...prescriptions in the United States alone. ACTOS is co-promoted by Takeda and Eli Lilly...
- ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic...
- Press release article from: PR Newswire September 19, 2007 700+ words
...of Diabetes demonstrate the ability of ACTOS(R) (pioglitazone HCl) to reduce the...disease in patients with type 2 diabetes. ACTOS is an oral antidiabetic agent for type...that therapeutic regimens that included ACTOS were associated with reductions in the...
- ACTOS(R) (pioglitazone HCl) Shows Sustained Efficacy Throughout Two-Year Period...
- Press release article from: PR Newswire June 5, 2004 700+ words
...studies using the oral antidiabetic drug ACTOS(R) (pioglitazone HCl) alone, and...diabetes, the data being presented today on ACTOS help physicians better understand the drug...year period, compared the effects of ACTOS either alone or in combination with two...